![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, February 24, 2021 2:14:39 PM
https://pubmed.ncbi.nlm.nih.gov/32861702/
Results: Among 1316 OSCC patients treated with curative-intent; 108 patients (8%) received non-operative management due to: medical inoperability (n = 14, 13%), surgical unresectability (n = 8, 7%), patient declined surgery (n = 15, 14%), attempted preservation of oral structure/function in view of required extensive surgery (n = 53, 49%) or extensive oropharyngeal involvement (n = 18, 17%).
Surgery is the main treatment modality for OSCC while postoperative radiation therapy (PORT) is indicated mainly for patients with advanced disease (e.g. pT3-4, pN2-3) or adverse pathologic/treatment features (e.g. close resection margin), and concurrent chemotherapy with PORT for patients with high risk features (positive microscopic resection margin[s] and/or pathologic extranodal extension) [1], [2], [3], [4], [5]
Almost everyone gets surgery if they can. The sooner the better.
Dr. Sonis didn't say anything about brilacidin other than the excerpt I posted. I don't know how he feels about it.
I think it's worth another trial if we have the money to risk. It is a big market, and there is a strong need for some drug to help.
Soligenix trial failed on top line for their phase 3 trial in December 2020. It looks like Sonis wrote the article in October 2020, so that's probably why he said no definitive results for a while. SGNX trial was the most advanced.
https://apnews.com/press-release/pr-newswire/business-technology-public-health-government-business-and-finance-health-care-policy-2a78c97ebf2e64fb5d3162a46b4e8cda
Will see if they go after secondary endpoints for approval or scrap the program.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM